|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bellissimo F, Pinzone MR, Cacopardo B and
Nunnari G: Diagnostic and therapeutic management of hepatocellular
carcinoma. World J Gastroenterol. 21:12003–12021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Intaraprasong P, Siramolpiwat S and
Vilaichone RK: Advances in management of hepatocellular carcinoma.
Asian Pac J Cancer Prev. 17:3697–3703. 2016.PubMed/NCBI
|
|
5
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tosi A, Dalla Santa S, Cappuzzello E,
Marotta C, Walerich D, Del Sal G, Zanovello P, Sommaggio R and
Rosato A: Identification of a HLA-A*0201-restricted immunogenic
epitope from the universal tumor antigen DEPDC1. Oncoimmunology.
6:e13133712017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kanehira M, Harada Y, Takata R, Shuin T,
Miki T, Fujioka T, Nakamura Y and Katagiri T: Involvement of
upregulation of DEPDC1 (DEP domain containing 1) in bladder
carcinogenesis. Oncogene. 26:6448–6455. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kikuchi R, Sampetrean O, Saya H, Yoshida K
and Toda M: Functional analysis of the DEPDC1 oncoantigen in
malignant glioma and brain tumor initiating cells. J Neurooncol.
133:297–307. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng X, Zhang C, Zhu L, Zhang L, Li H, He
L, Mi Y, Wang Y, Zhu J and Bu Y: DEPDC1 is required for cell cycle
progression and motility in nasopharyngeal carcinoma. Oncotarget.
8:63605–63619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mi Y, Zhang C, Bu Y, Zhang Y, He L, Li H,
Zhu H, Li Y, Lei Y and Zhu J: DEPDC1 is a novel cell cycle related
gene that regulates mitotic progression. BMB Rep. 48:413–418. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuan SG, Liao WJ, Yang JJ, Huang GJ and
Huang ZQ: DEP domain containing 1 is a novel diagnostic marker and
prognostic predictor for hepatocellular carcinoma. Asian Pac J
Cancer Prev. 15:10917–10922. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li A, Wang Q, He G, Jin J and Huang G: DEP
domain containing 1 suppresses apoptosis via inhibition of A20
expression, which activates the nuclear factor κB signaling pathway
in HepG2 cells. Oncol Lett. 16:949–955. 2018.PubMed/NCBI
|
|
13
|
Qu D, Cui F, Lu D, Yang Y and Xu Y: DEP
domain containing 1 predicts prognosis of hepatocellular carcinoma
patients and regulates tumor proliferation and metastasis. Cancer
Sci. 110:157–165. 2019.PubMed/NCBI
|
|
14
|
Du D, Liu Y, Qian H, Zhang B, Tang X,
Zhang T and Liu W: The effects of the CCR6/CCL20 biological axis on
the invasion and metastasis of hepatocellular carcinoma. Int J Mol
Sci. 15:6441–6452. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang F and Geng XP: Chemokines and
hepatocellular carcinoma. World J Gastroenterol. 16:1832–1836.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Benkheil M, Van Haele M, Roskams T,
Laporte M, Noppen S, Abbasi K, Delang L, Neyts J and Liekens S:
CCL20, a direct-acting pro-angiogenic chemokine induced by
hepatitis C virus (HCV): Potential role in HCV-related liver
cancer. Exp Cell Res. 372:168–177. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berretta M, Rinaldi L, Di Benedetto F,
Lleshi A, De Re V, Facchini G, De Paoli P and Di Francia R:
Angiogenesis inhibitors for the treatment of hepatocellular
carcinoma. Front Pharmaco. 7:4282016.
|
|
18
|
Zhu H, Gan X, Jiang X, Diao S, Wu H and Hu
J: ALKBH5 inhibited autophagy of epithelial ovarian cancer through
miR-7 and BCL-2. J Exp Clin Cancer Res. 38:1632019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen XY, Wang Q, Gu K, Li A, Fu X, Wang Y,
Gu W and Wen Y: Effect of YAP on an immortalized periodontal
ligament stem cell line. Stem Cells Int. 2019:68040362019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fang JH, Zhou HC, Zeng C, Yang J, Liu Y,
Huang X, Zhang JP, Guan XY and Zhuang SM: MicroRNA-29b suppresses
tumor angiogenesis, invasion, and metastasis by regulating matrix
metalloproteinase 2 expression. Hepatology. 54:1729–1740. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang C, Xu Y, Cheng F, Hu Y, Yang S, Rao J
and Wang X: miR-1301 inhibits hepatocellular carcinoma cell
migration, invasion, and angiogenesis by decreasing Wnt/β-catenin
signaling through targeting BCL9. Cell Death Dis. 8:e29992017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marsigliante S, Vetrugno C and Muscella A:
CCL20 induces migration and proliferation on breast epithelial
cells. J Cell Physiol. 228:1873–1883. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ramalho-Carvalho J, Martins JB, Cekaite L,
Sveen A, Torres-Ferreira J, Graça I, Costa-Pinheiro P, Eilertsen
IA, Antunes L, Oliveira J, et al: Epigenetic disruption of miR-130a
promotes prostate cancer by targeting SEC23B and DEPDC1. Cancer
Lett. 385:150–159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang L, Chen K, Cai ZP, Chen FC, Shen HY,
Zhao WH, Yang SJ, Chen XB, Tang GX and Lin X: DEPDC1 promotes cell
proliferation and tumor growth via activation of E2F signaling in
prostate cancer. Biochem Biophys Res Commun. 490:707–712. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brand S, Olszak T, Beigel F, Diebold J,
Otte JM, Eichhorst ST, Göke B and Dambacher J: Cell differentiation
dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt
signaling resulting in proliferation and migration of colorectal
cancer cells. J Cell Biochem. 97:709–723. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Frick VO, Rubie C, Keilholz U and Ghadjar
P: Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal
malignancy: An overview. World J Gastroenterol. 22:833–841. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang XP, Hu ZJ, Meng AH, Duan GC, Zhao QT
and Yang J: Role of CCL20/CCR6 and the ERK signaling pathway in
lung adenocarcinoma. Oncol Lett. 14:8183–8189. 2017.PubMed/NCBI
|
|
29
|
Han G, Wu D, Yang Y, Li Z, Zhang J and Li
C: CrkL meditates CCL20/CCR6-induced EMT in gastric cancer.
Cytokine. 76:163–169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ghadjar P, Rubie C, Aebersold DM and
Keilholz U: The chemokine CCL20 and its receptor CCR6 in human
malignancy with focus on colorectal cancer. Int J Cancer.
125:741–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nandi B, Pai C, Huang Q, Prabhala RH,
Munshi NC and Gold JS: CCR6, the sole receptor for the chemokine
CCL20, promotes spontaneous intestinal tumorigenesis. PLoS One.
9:e975662014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rubie C, Frick VO, Wagner M, Rau B, Weber
C, Kruse B, Kempf K, Tilton B, König J and Schilling M: Enhanced
expression and clinical significance of CC-chemokine MIP-3 alpha in
hepatocellular carcinoma. Scand J Immunol. 63:468–477. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hou KZ, Fu ZQ and Gong H: Chemokine ligand
20 enhances progression of hepatocellular carcinoma via
epithelial-mesenchymal transition. World J Gastroenterol.
21:475–483. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fernandez M, Semela D, Bruix J, Colle I,
Pinzani M and Bosch J: Angiogenesis in liver disease. J Hepatol.
50:604–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
